S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:TGTX

TG Therapeutics Competitors

$49.62
-1.57 (-3.07 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$48.56
Now: $49.62
$51.54
50-Day Range
$27.13
MA: $45.61
$54.90
52-Week Range
$6.34
Now: $49.62
$56.74
Volume1.80 million shs
Average Volume1.81 million shs
Market Capitalization$6.52 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.24

Competitors

TG Therapeutics (NASDAQ:TGTX) Vs. RPRX, ALNY, CTLT, HZNP, BMRN, and ELAN

Should you be buying TGTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to TG Therapeutics, including Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), Catalent (CTLT), Horizon Therapeutics Public (HZNP), BioMarin Pharmaceutical (BMRN), and Elanco Animal Health (ELAN).

Royalty Pharma (NASDAQ:RPRX) and TG Therapeutics (NASDAQ:TGTX) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Royalty Pharma and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
TG Therapeutics-135,198.03%-384.84%-121.26%

Insider and Institutional Ownership

36.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 66.3% of TG Therapeutics shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Royalty Pharma and TG Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
TG Therapeutics00503.00

Royalty Pharma currently has a consensus price target of $51.8750, indicating a potential downside of 0.14%. TG Therapeutics has a consensus price target of $48.80, indicating a potential downside of 1.65%. Given Royalty Pharma's higher probable upside, research analysts plainly believe Royalty Pharma is more favorable than TG Therapeutics.

Valuation & Earnings

This table compares Royalty Pharma and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
TG Therapeutics$150,000.0043,496.89$-172,870,000.00($1.83)-27.11

Royalty Pharma has higher earnings, but lower revenue than TG Therapeutics.

Summary

TG Therapeutics beats Royalty Pharma on 5 of the 9 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Alnylam Pharmaceuticals and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
TG Therapeutics-135,198.03%-384.84%-121.26%

Insider and Institutional Ownership

92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 66.3% of TG Therapeutics shares are held by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Alnylam Pharmaceuticals and TG Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals161102.56
TG Therapeutics00503.00

Alnylam Pharmaceuticals currently has a consensus price target of $159.0556, indicating a potential downside of 4.39%. TG Therapeutics has a consensus price target of $48.80, indicating a potential downside of 1.65%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Alnylam Pharmaceuticals.

Volatility & Risk

Alnylam Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.

Valuation & Earnings

This table compares Alnylam Pharmaceuticals and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million87.95$-886,120,000.00($8.11)-20.51
TG Therapeutics$150,000.0043,496.89$-172,870,000.00($1.83)-27.11

TG Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. TG Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Catalent (NYSE:CTLT) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Catalent and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
TG Therapeutics-135,198.03%-384.84%-121.26%

Insider and Institutional Ownership

97.8% of Catalent shares are held by institutional investors. Comparatively, 66.3% of TG Therapeutics shares are held by institutional investors. 1.0% of Catalent shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Catalent and TG Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01802.89
TG Therapeutics00503.00

Catalent currently has a consensus price target of $108.2222, indicating a potential downside of 6.30%. TG Therapeutics has a consensus price target of $48.80, indicating a potential downside of 1.65%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Catalent.

Volatility & Risk

Catalent has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.

Valuation & Earnings

This table compares Catalent and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.15$173 million$1.8861.44
TG Therapeutics$150,000.0043,496.89$-172,870,000.00($1.83)-27.11

Catalent has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Summary

Catalent beats TG Therapeutics on 9 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Valuation & Earnings

This table compares Horizon Therapeutics Public and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion13.36$573.02 million$1.9440.58
TG Therapeutics$150,000.0043,496.89$-172,870,000.00($1.83)-27.11

Horizon Therapeutics Public has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Horizon Therapeutics Public and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
TG Therapeutics-135,198.03%-384.84%-121.26%

Volatility & Risk

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.

Insider and Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 66.3% of TG Therapeutics shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Horizon Therapeutics Public and TG Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
TG Therapeutics00503.00

Horizon Therapeutics Public currently has a consensus price target of $93.6667, indicating a potential upside of 18.99%. TG Therapeutics has a consensus price target of $48.80, indicating a potential downside of 1.65%. Given Horizon Therapeutics Public's higher probable upside, research analysts plainly believe Horizon Therapeutics Public is more favorable than TG Therapeutics.

Summary

Horizon Therapeutics Public beats TG Therapeutics on 10 of the 13 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares BioMarin Pharmaceutical and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$1.70 billion8.84$-23,850,000.00$0.071,185.29
TG Therapeutics$150,000.0043,496.89$-172,870,000.00($1.83)-27.11

BioMarin Pharmaceutical has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioMarin Pharmaceutical and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioMarin Pharmaceutical45.74%4.34%2.84%
TG Therapeutics-135,198.03%-384.84%-121.26%

Volatility & Risk

BioMarin Pharmaceutical has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500.

Insider & Institutional Ownership

97.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 66.3% of TG Therapeutics shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for BioMarin Pharmaceutical and TG Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioMarin Pharmaceutical091102.55
TG Therapeutics00503.00

BioMarin Pharmaceutical currently has a consensus price target of $116.50, indicating a potential upside of 40.41%. TG Therapeutics has a consensus price target of $48.80, indicating a potential downside of 1.65%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than TG Therapeutics.

Summary

BioMarin Pharmaceutical beats TG Therapeutics on 10 of the 14 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Elanco Animal Health and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion4.84$67.90 million$1.0629.73
TG Therapeutics$150,000.0043,496.89$-172,870,000.00($1.83)-27.11

Elanco Animal Health has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
TG Therapeutics-135,198.03%-384.84%-121.26%

Volatility & Risk

Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500.

Insider & Institutional Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. Comparatively, 66.3% of TG Therapeutics shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Elanco Animal Health and TG Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health23502.30
TG Therapeutics00503.00

Elanco Animal Health currently has a consensus price target of $29.2778, indicating a potential downside of 7.08%. TG Therapeutics has a consensus price target of $48.80, indicating a potential downside of 1.65%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Elanco Animal Health.

Summary

Elanco Animal Health beats TG Therapeutics on 7 of the 13 factors compared between the two stocks.

Ad Legacy Research
"Do This" Before January 20th
They called the 2020 crash 45 days early. Nobody expects what they're predicting now...

TG Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Royalty Pharma logo
RPRX
Royalty Pharma
1.4$51.95-1.3%$20.16 billionN/A0.00Dividend Increase
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$166.36-0.8%$19.33 billion$219.75 million-21.25Analyst Report
Insider Selling
Unusual Options Activity
Analyst Revision
Catalent logo
CTLT
Catalent
1.7$115.50-0.2%$19.02 billion$3.09 billion73.57Analyst Upgrade
Increase in Short Interest
Heavy News Reporting
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$78.72-0.2%$17.37 billion$1.30 billion21.51Insider Selling
Increase in Short Interest
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$82.97-1.9%$15.06 billion$1.70 billion18.99
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$31.51-0.4%$14.87 billion$3.07 billion-55.28Decrease in Short Interest
Heavy News Reporting
Grifols logo
GRFS
Grifols
1.2$19.08-0.4%$13.12 billion$5.71 billion17.04Analyst Upgrade
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$11.96-3.8%$13.06 billion$16.89 billion5.18
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.4$71.06-1.3%$11.78 billion$2.32 billion46.75
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.4$214.47-0.3%$10.78 billion$3.34 million-27.85Analyst Report
Heavy News Reporting
Zai Lab logo
ZLAB
Zai Lab
1.2$170.90-4.1%$9.93 billion$12.98 million-56.40Analyst Downgrade
Bausch Health Companies logo
BHC
Bausch Health Companies
1.5$26.37-0.2%$9.37 billion$8.60 billion-4.84Analyst Report
Decrease in Short Interest
Heavy News Reporting
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$167.71-1.1%$9.34 billion$2.16 billion52.91Unusual Options Activity
Heavy News Reporting
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.0$61.28-0.1%$8.57 billion$1.12 billion127.67
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.6$53.66-1.5%$8.53 billion$339.08 million-31.20
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$157.93-2.6%$8.44 billion$14.98 million-19.24Analyst Downgrade
High Trading Volume
Heavy News Reporting
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.3$137.97-1.4%$8.42 billion$103.71 million-26.43
BBIO
BridgeBio Pharma
1.6$68.61-1.6%$8.42 billion$40.56 million-20.12Analyst Upgrade
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$80.74-2.6%$8.30 billion$87.99 million-96.12Insider Selling
United Therapeutics logo
UTHR
United Therapeutics
1.4$172.82-3.2%$7.68 billion$1.45 billion17.74
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$90.32-0.5%$7.13 billion$380.83 million-12.87Analyst Report
Analyst Revision
Allakos logo
ALLK
Allakos
1.2$128.51-0.0%$6.75 billionN/A-46.90Analyst Report
Unusual Options Activity
Analyst Revision
Heavy News Reporting
Galapagos logo
GLPG
Galapagos
1.3$100.01-1.7%$6.54 billion$1.00 billion-15.15Heavy News Reporting
TPTX
Turning Point Therapeutics
1.5$131.60-4.1%$6.34 billionN/A-35.38Analyst Report
Analyst Revision
Heavy News Reporting
SDGR
Schrödinger
1.3$90.89-2.2%$6.32 billion$85.54 million0.00Insider Selling
Perrigo logo
PRGO
Perrigo
2.7$43.71-2.2%$5.97 billion$4.84 billion25.12
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$21.84-6.6%$5.69 billion$182.24 million-18.99
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.6$106.29-0.3%$5.63 billion$1.11 billion34.18
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$100.99-1.5%$5.63 billion$66.51 million18.63Analyst Report
Analyst Revision
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.6$84.91-8.1%$5.09 billionN/A-6.92
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$126.51-1.6%$4.92 billion$26.69 million-47.74Insider Selling
Decrease in Short Interest
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$91.38-5.9%$4.76 billion$6.87 million-7.74Unusual Options Activity
Heavy News Reporting
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$80.50-0.1%$4.68 billion$806.43 million-11.40Insider Selling
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$68.49-0.3%$4.67 billion$306.98 million-9.76Analyst Downgrade
Insider Selling
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.2$33.82-3.5%$4.51 billion$204.89 million-42.28Analyst Upgrade
ARVN
Arvinas
1.8$90.60-3.2%$4.39 billion$42.98 million-35.39Heavy News Reporting
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$62.02-2.2%$4.29 billion$36.13 million-92.57
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.7$135.73-1.5%$4.21 billion$311.33 million-78.91
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.8$52.40-2.3%$3.97 billionN/A-7.06Insider Selling
FibroGen logo
FGEN
FibroGen
1.6$43.23-0.4%$3.93 billion$256.58 million-16.56High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.6$111.93-7.2%$3.82 billion$26.52 million-10.43
Insmed logo
INSM
Insmed
1.3$36.24-3.1%$3.69 billion$136.47 million-13.94Analyst Downgrade
Alkermes logo
ALKS
Alkermes
1.2$22.37-1.7%$3.56 billion$1.17 billion-48.63
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$28.14-1.8%$3.27 billion$306.49 million31.62
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.2$73.68-4.7%$3.20 billion$421.03 million-294.72
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.8$45.67-0.6%$3.16 billion$117.91 million-9.26Analyst Report
ALXO
ALX Oncology
1.8$83.33-0.4%$3.09 billionN/A0.00Lockup Expiration
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$49.92-0.3%$3.08 billion$2.11 million-10.81
OPKO Health logo
OPK
OPKO Health
1.9$4.55-0.7%$3.05 billion$901.90 million-13.79
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$16.98-4.8%$3.05 billion$114.62 million-6.85High Trading Volume
This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.